Skip to main content

Table 2 Clinical characteristics

From: Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma

Patients n

Sex/Age (y)

Previous treatment

Response to FCR

Response to RIT

Follow up (mo) since RIT

1

F/68

CHOP/R,radiotherapy

CR

CR

104 alive in CR

2

F/66

Radiotherapy, CHOP/R

CR

CR

88 alive in CR

3

F/57

CHOP/R

PR

CR

99 alive in CR

4

F/67

CHOP/R, radiotherapy

CR

CR

13 dead in CR

5

M/46

CHOP/like, ASCT, IFN maintenance for 24 months

PR

CR

83 alive in CR

6

F/61

MACOPB/R

CR

CR

92 alive in CR

7

M/69

CHOP, FM/R, CyDex/R

CR

CR

30 dead in CR (t-MDS)

8

M/57

Chlorambucil, MACOPB/R

CR

CR

32 dead in CR

9

F/77

Chlorambucil, radiotherapy

CR

CR

99 alive in CR

  1. CHOP cyclophosfamide, doxorubicin, vincristine, prednisone; R Rituximab; MACOPB Methotrexate, Doxorubicin, cyclophoshamide, vincristine, prednisone, bleomycin; ASCT autologous stem cell transplantation; IFN alpha interferon, FM fludarabine, mitoxantrone; Cy Dex cyclophosphamide, dexamethasone; t-MDS treatment-related myelodysplastic syndrome